Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marko Skelin

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
Leukemia|August 23, 2019
Second primary malignancies in myeloproliferative neoplasms and the role of aspirinMarko Lucijanic, Marko Skelin, Rajko Kusec
European Heart Journal|July 20, 2019
The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetesMarko Skelin, Marko Lucijanic, Eugen Javor
The New England Journal of Medicine|June 30, 2021
Once-Weekly Semaglutide in Adults with Overweight or ObesityEugen Javor, Marko Lucijanić, Marko Skelin
Annals of Internal Medicine|October 5, 2020
Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic SyndromesMarko Lucijanic, Miran Lovrinov, Marko Skelin
Acta Dermatovenerologica Croatica : ADC|September 25, 2022
ScurvyIvan Krečak, Gordan Babić, Marko Skelin
European Journal of Heart Failure|August 7, 2018
Risk stratification according to insulin typeMarko Skelin, Marko Lucijanic, Eugen Javor
Expert Review of Hematology|April 1, 2023
Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia veraIvan Krecak, Marko Skelin, Srdan Verstovsek
Scandinavian Journal of Clinical and Laboratory Investigation|January 29, 2026
Increase in mean corpuscular volume during treatment with hydroxyurea in patients with essential thrombocythemia and polycythemia vera does not predict clinical outcomesIvan Krecak, Antonija Duzaic, Marko Skelin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2019
Above What Age Should Ibrutinib Not Be Given With R-CHOP to Patients With Non-GBC DLBCL?Marko Skelin, Marko Lucijanić, Tanja Miketic
JAMA|September 19, 2019
Catheter Ablation Compared With Drug Therapy for Atrial FibrillationMarko Lucijanic, Marko Skelin, Petar Skelin
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
Leukemia|August 23, 2019
Second primary malignancies in myeloproliferative neoplasms and the role of aspirinMarko Lucijanic, Marko Skelin, Rajko Kusec
European Heart Journal|July 20, 2019
The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetesMarko Skelin, Marko Lucijanic, Eugen Javor
The New England Journal of Medicine|June 30, 2021
Once-Weekly Semaglutide in Adults with Overweight or ObesityEugen Javor, Marko Lucijanić, Marko Skelin
Annals of Internal Medicine|October 5, 2020
Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic SyndromesMarko Lucijanic, Miran Lovrinov, Marko Skelin
Acta Dermatovenerologica Croatica : ADC|September 25, 2022
ScurvyIvan Krečak, Gordan Babić, Marko Skelin
European Journal of Heart Failure|August 7, 2018
Risk stratification according to insulin typeMarko Skelin, Marko Lucijanic, Eugen Javor
Expert Review of Hematology|April 1, 2023
Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia veraIvan Krecak, Marko Skelin, Srdan Verstovsek
Scandinavian Journal of Clinical and Laboratory Investigation|January 29, 2026
Increase in mean corpuscular volume during treatment with hydroxyurea in patients with essential thrombocythemia and polycythemia vera does not predict clinical outcomesIvan Krecak, Antonija Duzaic, Marko Skelin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2019
Above What Age Should Ibrutinib Not Be Given With R-CHOP to Patients With Non-GBC DLBCL?Marko Skelin, Marko Lucijanić, Tanja Miketic
JAMA|September 19, 2019
Catheter Ablation Compared With Drug Therapy for Atrial FibrillationMarko Lucijanic, Marko Skelin, Petar Skelin
Pageof 7